See your company through
BioAlma's eyes

Type your company name below. We'll build your competitive intelligence overview in seconds — for free.

This is just the beginning.

BioAlma builds custom intelligence boards for your company — populated with real data, updated continuously by AI.

🔒 Start trial
💊

Pipeline Intelligence

Track every drug candidate, target, and indication in your competitive landscape

🔒 Start trial
🔬

Clinical Trial Tracker

Real-time enrollment, site data, and milestone tracking across all active trials

🔒 Start trial
⚔️

Competitive Intelligence

Automated competitive event monitoring with impact assessments

🔒 Start trial
🧬

Disease Landscape

Epidemiology, treatment algorithms, and unmet need analysis

🔒 Start trial
📊

Scenario Analysis

Interactive "what-if" canvases with structured assumption modeling

🔒 Start trial
🏥

PI & Site Intelligence

Investigator profiles, site performance, and enrollment patterns

🔒 Start trial
💰

Financial Intelligence

Revenue forecasts, cash runway, and deal activity tracking

🔒 Start trial
🏪

Commercial Intelligence

Market sizing, launch tracking, and sales force analytics

🔒 Start trial
🎓

KOL Management

Key opinion leader identification, profiling, and engagement tracking

Capabilities that change the game

Beyond dashboards — BioAlma gives your team superpowers.

✨ Interactive

Scenario Analysis Canvas

Build visual scenario estimates in seconds. Model competitive launches, market sizing, and risk scenarios with drag-and-drop nodes. Your assumptions are structured, auditable, and shareable with your board.

  • Interactive node-based scenario builder
  • AI-generated assumptions with cited sources
  • Shareable canvases for board and investor prep
  • What-if modeling with instant recalculation
📊 QUESTION
GLP-1 obesity market by 2030?
💊 MARKET SIZE
Obesity: $130B TAM (2030)
Oral GLP-1: $48B segment
⚔️ COMPETITION
Wegovy, Zepbound + 12 in Ph3
Oral formulations: 5 programs
🟢 BEST CASE
Oral first-in-class
$8B peak sales
🟡 BASE CASE
3rd oral entrant
$3.2B peak sales
🔴 RISK
Muscle loss signal
Label restriction
📅 TIMELINE
Ph3 readout: Q4 2026
Filing: mid-2027
⚡ AI SYNTHESIS
Risk-adj. NPV: $4.7B (prob. weighted)
Based on 23 GLP-1 analogs • Updated live
Show me all Phase 3 obesity drugs grouped by mechanism
🧬 Found 14 Phase 3 programs in obesity. I've created a view grouped by MOA:

• GLP-1 Agonists (6)
• Dual GLP-1/GIP (3)
• Amylin Analogs (3)
• Myostatin Inhibitors (2)

✅ View created — check the new tab in Pipeline
Now add enrollment data and highlight who's recruiting fastest
🤖 Agentic AI

Build custom views by chatting

No SQL. No filters. No manual data entry. Just tell Alma what you want to see, and she builds it — live, on your dashboard. She queries real databases, researches competitors, and creates interactive views while you watch.

  • Natural language → instant dashboard views
  • Full database access — real queries, real data
  • Creates tables, charts, timelines, and cards
  • Researches and populates data autonomously